Leef Brands (LEEEF) Free Cash Flow (2025 - 2026)
Leef Brands (LEEEF) reported Free Cash Flow of -$99838.0 for Q1 2026, up 95.0% on a YoY basis from -$51198.0 in Q1 2025, and up 95.0% sequentially from -$2.0 million in Q1 2025.
Leef Brands (LEEEF) Free Cash Flow (2025 - 2026) Analysis & Trends
Leef Brands (LEEEF) has 2 years of Free Cash Flow data on file, last reported at -$99838.0 in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 95.0% year-over-year to -$99838.0; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (changed N/A YoY), and the FY2025 full-year result was -$978909.0, up 85.95% from the prior year.
- Free Cash Flow improved to -$99838.0 in Q1 2026, from -$2.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$99838.0 in Q1 2026 to a low of -$2.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Leef Brands | 51.94 Mn | 46.18 Mn | 4.62 Mn | -99,838.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99,838.00 |
| Mar 31, 2026 | -99,838.00 |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |